Moderna Inc (NASDAQ:MRNA) announced data from the AstraZeneca Plc (NASDAQ:AZN)-led Phase 2 (EPICCURE) study evaluating AZD8601 in patients undergoing coronary artery bypass grafting…
JMP Securities analyst Nicholas Jones maintains Opendoor Technologies (NASDAQ:OPEN) with a Market Outperform and lowers the price target from $9 to $4.5.